XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 295.2 $ 117.0
Marketable investment securities 70.9 33.7
Trade accounts receivable 93.6 89.5
Inventory 18.6 27.1
Prepaid taxes 0.4 108.4
Prepaid expenses and other current assets 20.2 13.7
Total current assets 498.9 389.4
Operating lease right-of-use assets 83.6 59.7
Long-term marketable investment securities 47.5 21.0
Property, plant, and equipment, net 43.4 40.7
Intangibles, net 414.8 576.5
Goodwill 239.7 329.2
Other assets 8.0 2.3
Total assets 1,335.9 1,418.8
Current liabilities:    
Accounts payable 15.7 20.5
Accrued liabilities 163.2 79.1
Current maturities of operating lease liabilities 12.8 13.6
Deferred revenues 11.5 32.7
Total current liabilities 203.2 145.9
Unrecognized tax benefits 32.0 30.5
Long-term deferred taxes 40.7 71.3
Noncurrent operating lease liabilities 80.7 50.6
Long-term debt 0.0 224.8
Other long-term liabilities 10.8 14.7
Total liabilities 367.4 537.8
Commitments and contingencies
Stockholders’ equity:    
Common stock, 79.7 million and 75.4 million shares outstanding at September 30, 2021 and December 31, 2020, respectively 0.8 0.8
Additional paid-in capital 1,218.8 1,109.5
Accumulated other comprehensive loss (4.4) (2.3)
Accumulated deficit (246.6) (227.0)
Total Myriad Genetics, Inc. stockholders’ equity 968.6 881.0
Non-controlling interest (0.1) 0.0
Total stockholders' equity 968.5 881.0
Total liabilities and stockholders’ equity $ 1,335.9 $ 1,418.8